Agomab Therapeutics files for United States initial public offering as market conditions improve
Belgium-based biopharmaceutical firm Agomab Therapeutics filed for a U.S. initial public offering on Friday. The firm intends to list on the Nasdaq exchange.
Insights:
Agomab Therapeutics , a biopharmaceutical company based in Belgium 
BE, filed for an initial public offering in the United States on Friday, January 16, 2026. This filing represents the first concrete capital markets action by a late-stage biopharmaceutical company in an anticipated favorable IPO environment for 2026. The company intends to list its common stock on the Nasdaq under the ticker symbol AGMB.
BE, filed for an initial public offering in the United States on Friday, January 16, 2026. This filing represents the first concrete capital markets action by a late-stage biopharmaceutical company in an anticipated favorable IPO environment for 2026. The company intends to list its common stock on the Nasdaq under the ticker symbol AGMB.The underwriting syndicate for the offering includes JPMorgan Chase & Co. , Morgan Stanley , Leerink Partners, and Van Lanschot Kempen. This syndicate composition signals underwriter interest in the market for biopharmaceutical issues. Late-stage drugmakers have been encouraged to test the public markets in anticipation of specific conditions in 2026.
